Get the Stockscreener App
0.4819
5.52%
0.0252
Bioatla Inc stock is traded at $0.4819, with a volume of 268.55K.
It is up +5.52% in the last 24 hours and up +1.39% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.4567
Open:
$0.4611
24h Volume:
268.55K
Relative Volume:
0.48
Market Cap:
$23.89M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1861
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
+17.82%
1M Performance:
+1.39%
6M Performance:
-70.62%
1Y Performance:
-70.79%
1-Day Range:
$0.46
$0.4973
1-Week Range:
$0.411
$0.5583
52-Week Range:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.4819 | 23.89M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN
Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister
BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
BioAtla reports promising trial results for cancer drug - Investing.com
BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - The Manila Times
BioAtla's New Cancer Drug Achieves 13x Better Response Rate Than Standard Treatment in Phase 2 Trial - Stock Titan
BioAtla’s SWOT analysis: CAB platform stock faces pivotal year amid clinical trials - Investing.com Nigeria
Dimensional Fund Advisors LP Sells 86,264 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla receives Nasdaq delisting warning By Investing.com - Investing.com India
BioAtla receives Nasdaq delisting warning - Investing.com Australia
BioAtla Receives Nasdaq Non-Compliance Notice - TipRanks
HC Wainwright Issues Negative Estimate for BioAtla Earnings - Defense World
HC Wainwright Predicts BioAtla’s Q1 Earnings (NASDAQ:BCAB) - Defense World
BioAtla Inc (NASDAQ: BCAB): Is Its Value Too High Compared To Others? - Stocksregister
Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Relay Therapeutics (RLAY) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
BioAtla stock holds $1 target, JMP affirms Market Outperform By Investing.com - Investing.com Nigeria
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus By Investing.com - Investing.com India
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus - Investing.com Australia
Bioatla Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gaining Ground: BioAtla Inc (BCAB) Closes Lower at 0.48, Down -8.19 - DWinneX
BioAtla, Inc. (NASDAQ:BCAB) Q1 2025 Earnings Call Transcript - Insider Monkey
BioAtla Q1 2025 Earnings Call Transcript - MarketBeat
BioAtla (NASDAQ:BCAB) vs. Novavax (NASDAQ:NVAX) Head-To-Head Comparison - Defense World
BioAtla Inc (BCAB) Q1 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... By GuruFocus - Investing.com Canada
Bioatla, Inc. Earnings Call Highlights Clinical Success - TipRanks
BioAtla, Inc. Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations - Investing.com
BioAtla, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BCAB) - Seeking Alpha
BioAtla (BCAB) Advances Cancer Treatment with Promising Study Re - GuruFocus
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations By Investing.com - Investing.com UK
BioAtla (BCAB) Advances Cancer Treatment with Promising Study Results | BCAB Stock News - GuruFocus
BioAtla reports Q1 EPS (26c), consensus (29c) - TipRanks
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress - The Manila Times
BioAtla Reports Breakthrough: Cancer Drug Triples Survival Rate vs Standard Treatment in Lung Cancer Study - Stock Titan
BioAtla, Inc. (NASDAQ:BCAB) Shares Acquired by Renaissance Technologies LLC - Defense World
There is no doubt that BioAtla Inc (BCAB) ticks all the boxes. - Sete News
BioAtla Inc (BCAB) shows promising results - uspostnews.com
BioAtla Reveals Next-Gen Cancer Treatment Progress: Key Updates Coming at Citizens Conference - Stock Titan
BCAB: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
An Analysis of BioAtla Inc (BCAB)’s Potential Price Growth - knoxdaily.com
BioAtla to Participate in the Citizens Life Sciences Conference - TradingView
BioAtla Q1 2025 Earnings: Biotech Leader to Share Latest Cancer Treatment Progress on May 6 - Stock Titan
Bank of Montreal Can Sells 522,252 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla Inc (BCAB) Could Be Worth Considering For The Next Few Weeks - Stocksregister
BioAtla announces poster presentations at 2025 AACR meeting - TipRanks
How did BioAtla Inc (BCAB) fare last session? - uspostnews.com
BCAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
BioAtla (BCAB) to Showcase Innovative Cancer Research at 2025 Co - GuruFocus
BioAtla Announces Poster Presentations At The 2025 American Association For Cancer Research (Aacr) Annual Meeting - TradingView
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):